|
Report Date : |
26.06.2012 |
IDENTIFICATION DETAILS
|
Name : |
BARRETT HODGSON |
|
|
|
|
Registered Office : |
F-423, S.I.T.E., |
|
|
|
|
Country : |
|
|
|
|
|
Year of Establishment : |
1992 |
|
|
|
|
Com. Reg. No.: |
0028289 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture &
Marketing of Pharmaceutical Products |
|
|
|
|
No. of Employees : |
312 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Good |
|
Payment Behaviour : |
Regular |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
Pakistan |
B2 |
B2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
BARRETT HODGSON PAKISTAN (PRIVATE) LTD
|
Registered
Address & Factory |
|
F-423, S.I.T.E., Karachi, Pakistan |
|
Tel # |
92 (21) 32570651 - 57 (7 Lines) |
|
Fax # |
92 (21) 32568827, 32570650 |
|
Nature of Business |
Manufacture
& Marketing of Pharmaceutical Products |
|
Year Established |
1992 |
|
Registration # |
0028289 |
|
Address |
1-A, Shahid Plaza, Jinnah Avenue, Blue Area, Islamabad, Pakistan |
|
Tel # |
92 (51) 2277098, 2270275 |
|
Fax # |
92 (51) 2270277 |
|
Address |
175, Gen. Sarfraz Khan Road, Shadman-II, Lahore, Pakistan |
|
Tel # |
92 (42) 37562711, 37562705 |
|
Fax # |
92 (42) 37582854 |
|
A.F. Ferguson & Co. (Chartered
Accountants) State Life Building, 1-C, Off: I.I. Chundrigar Road, Karachi, Pakistan |
|
Subject Company was established as a Private Limited Company in 1992 |
|
Authorized Capital |
Rs. 250,000,000/- divided into 2,500,000
shares of Rs. 100/- each |
|
Issued & Paid up Capital |
Rs. 136,570,000/- divided into 1,365,700
shares of Rs. 100/- each |
|
Names |
Nationality |
Address |
Designation |
|
Dr. Iram Afaq Mr. Tariq Amin Dr. M.S. Habib Mr. Shahid Mansoor Dr. Hasan Tharani Mr. S. Shakeel Ahmed |
Pakistani Pakistani Pakistani Pakistani Pakistani Pakistani |
166,
Khayaban-e-Shahbaz, Phase VI, DHA, Karachi House No. 34/II,
Khayaban-e-Badar, Phase-V, DHA, Karachi 166,
Khayaban-e-Shahbaz, Phase VI, DHA, Karachi House No. C-55,
Block 9, Gulshan-e-Iqbal, Karachi B-112, Block-10,
Gulshan-e-Iqbal, Karachi D/17, Askari-IV,
Apartment, Rashid Minhas Road, Karachi |
Chief Executive Director Director Director Director Director |
|
Names |
No. of Shares |
|
Barrett Hodgson Limited, U.K. Dr. M.S. Habib Mr. Benyamin Naeem Habib Dr. Iram Afaq |
1,207,279 57,599 100,821 1 |
A. Subsidiary
None
B. Associated
Companies
(1) Lahore Medical
Instruments (Pvt) Limited, Pakistan.
Manufacture & marketing of different pharmaceutical class like Anti
Biotic, Anti Malarials, Anti-Rheumatic, Antihistamine, Narcotic Analgesic, Non
Steroidal Respiratory Anti Inflamatory, Quinolones, Vitamins, Phenothiazine,
Hypolipidaemics, Muscle Relaxant, Amoebicide, Calcium-Antagonist, Cardio
Selective Beta Blocker with their brand names of ACICON, BAMBEC, BAYHEP, BETALOC ZOK, BETAXEN, BINADEX, BRICANYL,
CEFAMEZIN, CEFCOM, CEFIX, CEFIZOX, CEFNIR, CEFSPAN, CIPOCAINE, CIPOTIC, DOMEL,
DYNAQUIN, ERADEP, EXOCIN, FEBROL, FLUCOL, GENTICYN, GIXER, INOCEF, INOQUIN,
JECTOFER, LEVAQUIN, MOBIKARE GEL, MST CONTINUS, MYLAXON, OCUFEN, PENGLOBE,
PERSCH, PLENDIL, POLYFER, PRED FORTE, PULMICORT, QUINTEC, RECOL, ROMICEF,
SARTAN, WINTAX, XYLOAID, XYLOCAINE, ADRENALINE
312
The capacity and production of the company’s
plant is indeterminable as it is multi-product and involves varying processes
of manufacture
|
Year |
In Pak Rupees |
|
2010 |
500,000,000/- (Estimated) |
(1)
ASTRAZENECA, U.K.
(2)
ASTELLAS DEUTSCHLAND GMBH, GERMANY.
(3)
MIKA PHARMA GMBH, GERMANY.
(4)
ALLERGAN, U.S.A.
(5)
ZHEJIANG JINGXIN
PHARMACEUTICAL IMPORT & EXPORT, CHINA.
|
More than 100 Distributors in all over Pakistan |
|
Mainly to Asian, Middle East and European Countries |
(1)
Faysal Bank Limited,
Pakistan.
(2)
Habib Bank Limited,
Pakistan.
(3)
Habib Metropolitan Bank
Limited, Pakistan.
(4)
Standard Chartered Bank,
Pakistan.
(5)
Saudi Pak Commercial Bank
Limited, Pakistan.
(6)
ABN AMRO Bank, Pakistan.
·
Pakistan Pharmaceutical Manufacturers Associations.(PPMA)
·
Karachi Chamber of Commerce & Industry.(KCCI)
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 95.60 |
|
UK Pound |
1 |
Rs. 149.00 |
|
Euro |
1 |
Rs. 119.80 |
Subject Company was established in 1992 and
is engaged in manufacturing & marketing of Pharmaceutical Products. Market reputation
is extremely good. Directors are reported as resourceful and experienced
professionals. Trade relations are reported as fair. The Company can be
considered for normal business dealings at usual trade terms and conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.56.53 |
|
|
1 |
Rs.88.09 |
|
Euro |
1 |
Rs.70.83 |
INFORMATION DETAILS
|
Report Prepared
by : |
PRL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.